Icagen, Inc. (ICFN) SEC Filing 8-K Material Event for the period ending Monday, June 19, 2017

Icagen, Inc.

CIK: 1518520 Ticker: ICFN

View differences made from one to another to evaluate Icagen, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Icagen, Inc..


Assess how Icagen, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Icagen, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Icagen, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ICFN
CIK: 1518520
Form Type: 8-K Corporate News
Accession Number: 0001213900-17-006677
Submitted to the SEC: Wed Jun 21 2017 7:52:07 AM EST
Accepted by the SEC: Wed Jun 21 2017
Period: Monday, June 19, 2017
Industry: Commercial Physical And Biological Research
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: